QGEN:NGS-Qiagen N.V. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 39.22

Change

-0.79 (-1.97)%

Market Cap

USD 6.46B

Volume

1.30M

Analyst Target

USD 52.64
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Qiagen NV provides sample and assay technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+2.97 (+1.45%)

USD 148.68B
A Agilent Technologies Inc

-0.36 (-0.26%)

USD 43.23B
IQV IQVIA Holdings Inc

-2.50 (-1.27%)

USD 36.97B
LH Laboratory Corporation of Amer..

+1.35 (+0.54%)

USD 20.54B
DGX Quest Diagnostics Incorporated

+0.39 (+0.23%)

USD 18.67B
CRL Charles River Laboratories

-2.75 (-1.67%)

USD 8.50B
VNRX Volitionrx Ltd

-0.01 (-1.36%)

USD 0.06B
ENZ Enzo Biochem Inc

+0.01 (+1.78%)

USD 0.03B
MTD Mettler-Toledo International I..

+0.20 (+0.02%)

N/A
TMO Thermo Fisher Scientific Inc

+6.97 (+1.31%)

N/A

ETFs Containing QGEN

EXIB:XETRA 8.69 % 0.00 %

N/A

N/A
TDXPEX:SW iShares TecDAX® UCITS ET.. 8.69 % 0.00 %

N/A

USD 5,933.97B
CB1TX:SW Lyxor 1 TecDAX (DR) UCITS.. 7.24 % 0.00 %

N/A

N/A
GN0M:XETRA 4.63 % 0.00 %

N/A

N/A
GNOM:SW Global X Genomics & Biote.. 4.63 % 0.00 %

-0.06 (0.00%)

USD 9.83M
GNOG:LSE Global X Genomics & Biote.. 4.54 % 0.00 %

-0.08 (0.00%)

USD 9.83M
DDOC:F 4.27 % 0.00 %

N/A

N/A
EDOC:SW Global X Telemedicine & D.. 4.03 % 0.00 %

-0.07 (0.00%)

N/A
ZLI:CA BMO Low Volatility Intern.. 1.68 % 0.42 %

+0.20 (+0.00%)

CAD 0.23B
MVAE:PA 0.77 % 0.00 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
JPED 0.00 % 0.74 %

N/A

N/A
CF1:PA Amundi ETF MSCI France UC.. 0.00 % 0.00 %

+1.10 (+0.00%)

USD 9.85M
E908:F 0.00 % 0.00 %

N/A

N/A
EXS2:F 0.00 % 0.00 %

N/A

N/A
C007:XETRA 0.00 % 0.00 %

N/A

N/A
E907:XETRA 0.00 % 0.00 %

N/A

N/A
E908:XETRA 0.00 % 0.00 %

N/A

N/A
ELF1:XETRA 0.00 % 0.00 %

N/A

N/A
EXS2:XETRA 0.00 % 0.00 %

N/A

N/A
EXS3:XETRA 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

-0.16 (0.00%)

USD 0.04B
DDOC:XETRA 0.00 % 0.00 %

N/A

N/A
DEAM:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.37% 17% F 5% F
Dividend Return 2.75% 100% F 95% A
Total Return -11.62% 17% F 6% D-
Trailing 12 Months  
Capital Gain -11.06% 46% F 16% F
Dividend Return 2.86% 100% F 44% F
Total Return -8.20% 46% F 16% F
Trailing 5 Years  
Capital Gain 2.01% 33% F 48% F
Dividend Return 6.81% 80% B- 19% F
Total Return 8.82% 33% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain -1.49% 23% F 25% F
Dividend Return -0.83% 23% F 17% F
Total Return 0.67% 86% B+ 16% F
Risk Return Profile  
Volatility (Standard Deviation) 11.50% 92% A 75% C
Risk Adjusted Return -7.19% 23% F 16% F
Market Capitalization 6.46B 44% F 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.20 25% 6%
Price/Book Ratio 2.73 67% 33%
Price / Cash Flow Ratio 20.99 33% 17%
Price/Free Cash Flow Ratio 27.36 11% 11%
Management Effectiveness  
Return on Equity 2.57% 33% 35%
Return on Invested Capital 6.70% 33% 53%
Return on Assets 4.84% 56% 73%
Debt to Equity Ratio 24.21% 67% 76%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.